Clinical Application of Screening for GJB2 Mutations before Cochlear Implantation in a Heterogeneous Population with High Rate of Autosomal Recessive Nonsyndromic Hearing Loss by Motasaddi Zarandy, Masoud et al.
SAGE-Hindawi Access to Research
Genetics Research International
Volume 2011, Article ID 787026, 6 pages
doi:10.4061/2011/787026
Research Article
Clinical Application of Screeningfor GJB2 Mutations before
Cochlear Implantation in a HeterogeneousPopulation with High
Rate of Autosomal Recessive NonsyndromicHearingLoss
MasoudMotasaddi Zarandy,1 MersedehRohanizadegan,2,3 HojjatSalmasian,2,4
Nooshin Nikzad,5 Niloofar Bazazzadegan,5 andMahdi Malekpour1,6
1ENT Research Center, Department of Otorhinolarygology, Head and Neck Surgery, Amir Alam Hospital,
Tehran University of Medical Sciences, Tehran 1145765111, Iran
2Students Scientiﬁc Research Center, Tehran University of Medical Science, Tehran 1417613151, Iran
3Department of Medicine, Columbia University, New York, NY 10032, USA
4Department of Biomedical Informatics, Columbia University, New York, NY 10032, USA
5Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
6Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
Correspondence should be addressed to Masoud Motasaddi Zarandy, motesadi@sina.tums.ac.ir
and Mahdi Malekpour, mahdi.malekpour@vanderbilt.edu
Received 6 June 2011; Revised 1 September 2011; Accepted 28 September 2011
Academic Editor: Karen Friderici
Copyright © 2011 Masoud Motasaddi Zarandy et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Clinical application of mutation screening and its eﬀect on the outcome of cochlear implantation is widely debated. We
investigated the eﬀect of mutations in GJB2 gene on the outcome of cochlear implantation in a population with a high rate of
consanguineous marriage and autosomal recessive nonsyndromic hearing loss. Two hundred and one children with profound
prelingual sensorineural hearing loss were included. Forty-six patients had 35delG in GJB2. Speech awareness thresholds (SATs)
and speech recognition thresholds (SRTs) improved following implantation, but there was no diﬀerence in performance between
patients with GJB2-related deafness versus control (all P>0.10). Both groups had produced their ﬁrst comprehensible words
within the same period of time following implantation (2.27 months in GJB2-related deaf versus 2.62 months in controls,
P = 0.22). Although our ﬁndings demonstrate the need to uncover unidentiﬁed genetic causes of hereditary deafness, they do
not support the current policy for genetic screening before cochlear implantation, nor prove a prognostic value.
1.Introduction
Hereditarysensorineural hearingimpairment (SNHI)aﬀects
2–4 children per 1000 in the developing countries [1].
Burden of hearing impairment is described in extenso and
is felt by the clinician and families taking care of the deaf
[2]. Early identiﬁcation of hearing loss and initiation of
rehabilitation measures are the cornerstones of language
development [3].
For patients with profound SNHI, cochlear implant (CI)
is considered to be an eﬀective intervention bypassing the
inner ear organs and activating the auditory nerve directly.
Outcome of CI diﬀers signiﬁcantly between the implantees.
Since the etiology and demographic data of the implantees is
diverse, diﬀerent factors could be attributed to the diﬀerence
of the CI success [4]. The operation is expensive and
requires advanced training, therefore, identiﬁcation of the
most important factors aﬀecting the outcome of CI becomes
necessary especially in settings with limited resources and a
need for judicious patient selection [5].
In the last two decades, molecular genetics had shed
light on many aspects of hereditary deafness and elucidated
the pathophysiology of deafness in some cases of genetic
hearing loss. A number of studies had argued that GJB22 Genetics Research International
mutations demonstrate a better language performance fol-
lowing cochlear implantation, but the justiﬁcations are not
persuasive and authors frequently suggested further studies
[6–9]. Since genetic testing is expensive and not covered by
most healthcare insurances, identiﬁcation of the role that
genetics plays in the outcome of CI is far beyond necessary.
In this study we investigated the role of commonly identiﬁed
genetic mutations and their association with subjective and
objective outcomes in a population of pediatric patients
with profound hearing impairment that received CI. This
population has a high rate of consanguineous marriage
and therefore high rate of autosomal recessive diseases,
which facilitated sampling nonsyndromic cases of congenital
hearing loss [10, 11].
2. Methods
2.1. Subject Recruitment and Preimplantation Evaluation.
Two hundred and one consecutive and unrelated children
with profound SNHI (108 boys and 93 girls) who underwent
CI from 2003 to 2006 were enrolled in this study. All children
were native Persian speakers and had been identiﬁed to
have hearing impairment before the age of 3, also known
as prelingual hearing impairment. All of these children
were found to be suﬀering from nonsyndromic hearing
impairment, which means no additional physical problem
had been identiﬁed accompanying their hearing loss. Com-
prehensive clinical evaluations were fulﬁlled for each child
encompassing history, physical examination, audiological
tests, radiological studies of the temporal bone, and genetic
testing. These evaluations were done free of charge for all the
candidates.
All the implantees had gone through 60 sessions of
mandatory oral and language rehabilitation classes. These
classes take 2 hours per session, and provide the minimum
of the required time for suﬃcient tonal information of
Persian language. All the parents and/or guardians of the
implantees had previously signed a written consent for
their implantation procedures and had exclusively signed a
second consent for this study. The procedure and studies had
been approved by the Institutional Review Board of Tehran
University of Medical Sciences.
2.2. Genetic Examination. Consenting subjects provided 7–
10 cc of whole blood from which DNA was extracted using
establishedtechniques.Sampleswerescreenedforthe35delG
allele of GJB2 using a previously described ARMS-PCR
method[12].All35delGhomozygoussampleswereexcluded
from further testing. In the remaining samples, GJB2 and
GJB6 mutation screening was completed using a previously
described method [12].
2.3. Evaluation of Speech Perception. The date on which the
CI recipient produced the ﬁrst comprehensible two-syllable
word was reported and conﬁrmed by an audiologist. Data
regarding the shape of audiogram and level of hearing was
collected before the CI surgery for both ears and at 1, 3,
6, 12, and after 12 months from the date of CI for the
implanted ear. None of the study subjects received bilateral
cochlear implants. After implantation, speech awareness
thresholds (SATs) were measured at 1 and 3 months and
speech recognition thresholds (SRTs) were measured at 6
and 12 months. Most comfortable level (MCL) was also
determined at 6 and 12 months. In some CI recipients,
additional testing was done within the ﬁrst 3 years following
surgery. Although newer tests for assessment of auditory
function exist, including the open-set and close-set tests,
in the lack of standardized equivalent tests in Persian, we
used level of hearing, SAT, SRT, and MCL to assess the
outcome of CI and compare it between the two arms of the
study.Weshouldhighlightthatresultsfromnonstandardized
tests that are equivalent to tests in English language were
all reproducing the same results but are excluded from the
analysis for the sake of robust standard comparisons to other
studies.
2.4. Statistical Analysis. SAT, SRT, and MCL were expressed
in dB referring to the hearing level; speech recognition and
word generation were compared to the genetic diagnosis.
Continuous variables were compared using the Student’s t-
test,ANOVA,andrepeatedmeasuresanalysis;chi-squarewas
used to compare dichotomous variables. All tests were two
tailed. Diﬀerences were reported as signiﬁcant if the P value
was less than 0.05. Because age at the time of implantation
could potentially confound the association between the
genetic status and some of the primary outcomes (e.g., time
of ﬁrst vocalization), we used linear regression models to
adjust the analyses for age.
3. Results
Genetic analysis identiﬁed 62 patients with mutations in
GJB2, and 35delG was the most frequent type of mutation.
Forty-six patients were found to have 35delG mutation in
GJB2: thirty (14.9%) were found to be homozygote for
35delG mutations and 13 (6.5%) were heterozygote; the
second mutation was not found in the remaining three
heterozygotes. Table 1 lists the mutations found in the 16
patients without 35delG. No GJB6 mutation was found in
our population.
Ethnicity of our patients and the ethnicity of the Iranian
population are shown in Table 2. In 124 families (61.7%)
parents had been consanguineous relatives of each other.
The mean age of implantation was 2.5 years (ranging from
8m o n t h st o5 . 5y e a r s ) .T h e yw e r ef o l l o w e df o ra na v e r a g e
of 3.72 years (standard deviation = 2.95 years), and their
age at last data point ranged between 2 and 14 years (mean
± standard deviation = 6.38 ± 3.37 years). Duration of
followup was not statistically diﬀerent among patients with
and without mutations (4.1 years versus 3.6 years, P = 0.234,
95% CI = −1.43 to 0.35 years, power > 99%).
Following implantation, audiograms improved from
severe-to-profound or profound levels before the surgery to
moderate-to-severe or moderate levels by 3 months after
surgery, all acquiring a ﬂat shape. By 6 months after surgery,
all audiograms were at moderate level or better. Nearly half
of implant recipients improved to mild hearing loss after
one year following implantation (Table 3). Comparison ofGenetics Research International 3
Table 1: GJB2 genotypes in patients carrying no 35delG mutations.
Homozygote mutations are marked with an asterisk.
Genotype Frequency Percent
V1531 4 25%
R184P∗ 2 12.5%
167DelT∗ 2 12.5%
V27I SNP∗ 2 12.5%
G130V 1 6.3%
235delC/R184P 1 6.3%
R127H 1 6.3%
SNP N26N∗ 16 . 3 %
R32C∗ 16 . 3 %
R151P∗ 16 . 3 %
Total 16 100%
Table 2: Ethnicity of the studied population compared to overall
composition in Iran.
Ethnicity Number Percentage Percentage in Iran
Fars 68 33.8 51
Turk 44 21.9 24
Gilak/Mazandarani 34 16.9 8
Kurd 16 8.0 7
Lur 13 6.5 2
Arab 9 4.5 3
Pakistani 1 0.5 <1
Afghan 1 0.5 <1
Mixed 14 7.0 5 (other)
Not known 1 0.5 —
Total 201 100 100
level of hearing among carriers of GJB2 mutations versus
control yielded no signiﬁcant association (P>0.10 in all
comparisons).
At baseline, level of hearing had not been signiﬁcantly
diﬀerent between the GJB2 mutation carriers and the rest of
implantees (P = 0.053, power = 96.65%, alpha level 0.05).
In addition, there was no correlation between GJB2-related
deafness and other demographic factors including race of
patient or parents, education level, and occupational status
of parents (ANOVA P>0.10). Although level of hearing
had improved over time, there was no statistically signiﬁcant
diﬀerence in this improvement between the carriers of GJB2
mutations and the rest of the implantees (P = 0.18).
Regression in each measured frequency of the audiograms
over the period of followup did not show a signiﬁcant
diﬀerencebetweenthe GJB2mutation carriersandtherestof
thepatients(ANOVAP>0.2,statisticalpower=77.3%).The
very same statistically similar ﬁndings were seen for the SAT,
SRT, and MCL measurements at the speciﬁed times (all P>
0.10, statistical power > 70% in all cases). Results remained
unchanged after correcting for age at the time of operation
or age at the time of diagnosis. Table 4 shows the measured
SAT, SRT, and MCL values at the speciﬁed times, but further
subcategorizes the group with GJB2 mutations into two
subgroups.Thetimeofﬁrstvocalizationdidnotsigniﬁcantly
diﬀer between the two groups (2.27 months for GJB2-related
deaf versus 2.62 for controls, P = 0.22, statistical power =
90.4%).Theassociationbetween GJB2-mutationandtimeof
ﬁrst vocalization remained insigniﬁcant after correction for
age at the time of operation (P = 0.345) or age at the time of
diagnosis (P = 0.215).
Repeated measures analysis showed that although the
level of hearing had signiﬁcantly improved over time, the
diﬀerence was independent of the genetic status of patients
(P = 0.971). Similarly, presence of 35delG had no eﬀect
on the improvement observed in SRT (P = 0.973) or MCL
(P = 0.511) over time. Figures 1 and 2 depict that the
trend of improvement of these variables was similar in the
two groups. We repeated this analysis by restricting it to
patients with homozygote 35delG mutation, and yielded
similar results: the presence of homozygote 35delG was not
associated with improvements observed in SRT (P = 0.581)
or MCL (P = 0.253).
4. Discussion
This is the largest study to date on prelingual nonsyndromic
deaf population investigating the eﬀect of GJB2 mutations
on the outcome of cochlear implantation. We found that
GJB2 mutations do not have any signiﬁcant relation with the
speech perception abilities following CI compared to non-
GJB2-related patients. In addition, no correlation was found
between the genetic mutation and time to vocalization of
the ﬁrst comprehensible word. Other variables which had
been shown to aﬀe c tt h eo u t c o m eo fC Is u c ha sa g ea t
implantation, duration of implant use, and residual hearing
beforeCIwerekeptconstantinthisstudythroughthepatient
selection criteria or at the time of analysis. In this regard,
our studied population constitutes a relatively homogenous
population to study the eﬀect of genetic factors. Our study
also shows that the genetic change in a large number of
patients with hereditary SNHI remains unknown in our
population.
At the time of clinical introduction of GJB2 mutation
screening for deaf patients, many came to the conclusion of
GJB2 superiority in CI recipients [9]. A primary study on the
CI recipients had identiﬁed a better response in the carriers
of mutations in GJB2. An issue raised about this study was
patient selection and matched controls where a clear etiology
ofdeafnessincontrolsisnotprovided[13].Thesamejournal
published another study in the following year which showed
no beneﬁt in the carriers of GJB2 mutations [8]. This is
the year when further studies had come to a conclusion
of superiority of GJB2 mutation carriers over non-GJB2
controls [14]. The concept of GJB2 performance superiority
in CI performance was additionally reinforced within two
years [7].
Correct selection of the matched controls for any
deduction is emphasized in the works of other authorities
[15]. More recent studies have been cautious in making
any suggestion regarding the superiority of genetic deafness
over controls for the CI outcome [16]. In 2008, a study
on Taiwanese patients reported the same positive eﬀect for4 Genetics Research International
Table 3: Percentages showing the shape of audiograms and level of hearing at the times measured.
Shape of audiogram Before CI 1mo 3mo 6mo 12mo 12mo <
Fragmentary 52.1 — — — — —
Descending 46.6 — — — — —
Flat 1.4 100 100 100 100 100
Level of hearing
Profound 82.2 — — — — —
Severe-to-profound 17.8 — — — — —
Moderate-to-severe — 13.9 2.8 — — —
Moderate — 86.1 97.2 95.7 81.2 53.8
Mild — — — 4.3 18.8 46.2
Table 4: SAT, SRT, and MCL measurements and gender distribution of patients in the sample. Patients with GJB2 mutations are sub-
categorized into two columns, based on the presence of 35delG variant. Continuous values are presented as mean ± standard deviation;
dichotomous values are presented as frequency (percentage in row). Values pertain to the operated ear only. Unit of measurement: dB.
35delG mutation Non-35delG mutation No mutation
Gender Male 26 (56.5%) 8 (50%) 74 (53.2%)
Female 20 (43.5%) 8 (50%) 65 (46.8%)
SAT N = 72 N = 20 N = 5 N = 47
One month after surgery 43.6 ± 3.8 41.7 ± 2.9 44.1 ± 5.1
Three months after surgery 40.7 ± 5.3 35.0 ± 0∗ 39.7 ± 4.8
SRT N = 65 N = 19 N = 4 N = 42
Six months after surgery 40.8 ± 4.5 43.3 ± 2.9 39.2 ± 4.7
Twelve months after surgery 38.5 ± 4.7 37.7 ± 7.6 37.3 ± 4.1
MCL N = 45 N = 13 N = 4 N = 28
Six months after surgery 71.8 ± 4.0 75.0 ± 0.0∗ 72.1 ± 4.4
Twelve months after surgery 69.7 ± 6.0 66.7 ± 7.6 71.5 ± 4.4
Total∗∗ 46 16 139
∗All measured values were equal, hence a standard deviation equaling zero.
∗∗Not all values presented in the table were available for the total number of subjects in each group.
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Figure 1: Changes in SRT following implantations in patients with
35delG mutation versus others with non-GJB2-related deafness.
genetic cases of hearing loss on the outcome of the CI.
Although they had a very small number of GJB2 patients
andthelargerproportion ofidentiﬁed geneticcasesweredue
to SLC26A4, they proposed an intact auditory nerve as the
cause of a better outcome in their implantees but had not
studied or proposed other possible causes in the rest of their
population. While a syndromic cause is usually identiﬁed
following a physical examination, lack of the diagnosis in the
rest of the recipients brings them into the category of other
nonsyndromic causes of deafness that had not been tested.
It that case, the theory of an intact auditory nerve could not
be readily relied on [6]. One of the advantages of our study
stems from the selection of nonsyndromic patients with a
prelingual diagnosis of profound hearing loss, which makes
the comparison easier by keeping more variables constant.
Sampling nonsyndromic patients was particularly feasible in
our study setting because of high rate of consanguinity of
parents in the target population [10, 11].
Justiﬁcation of a better auditory perception in genetic
cases—including GJB2 mutation carriers—by other author-
ities mainly lies in the intactness of the auditory nerve.
In a population with such a high rate of consanguineous
marriages and taking into consideration the high rate of
deafness presenting as a nonsyndromic disease in general,
correct selection of patients through physical examination,
history taking, and required imaging modalities will choose
a high rate of patients with intact auditory nerves. It shouldGenetics Research International 5
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Figure 2:ChangesinMCLfollowingimplantationsinpatientswith
35delG mutation versus others with non-GJB2-related deafness.
be highlighted that if only intact auditory nerve had been the
support of justiﬁcations of a better response in congenital
deafness, a much more simple way to choose such patients
wouldhavebeenthroughelectrophysiologicaltestswhichare
much less expensive compared to genetic tests.
In many articles which suggest a genetic eﬀect on the
outcome of CI, the studied population compromises a large
variety of cases in which many syndromic deaf patients
are also studied [7, 9, 13, 14]. This might have been a
confounding factor in their ﬁnal conclusion. The other
question which remains to be answered by supporters of
a positive genetic eﬀect is where the problem had been in
their patients with no identiﬁed genetic cause and still a
functioning auditory nerve. The answer to this question
mightshedlightonthereportedeﬀectofgenetichearingloss
on the outcome of CI.
To the contrary, a perfectly matched, yet smaller study,
on CI patients found that there is no advantage in connexin-
associated deafness over other patients [17]. The same
results had been reported through another two-center study
earlier [18]. As indicated in our study, if the patients are
selected through a delicate physical examination and other
necessary investigations before CI, the acceptable outcome
of the implantation would be assured. This will once again
emphasize the importance of selecting a comparable control
group in making a ﬁnal conclusion [17]. The similarity of
response to CI is also claimed in a recent study [19]. Very
interestingly, a current publication on GJB2 and CI outcome
had found a poorer outcome following implantation in GJB2
carrying patients [20]. All these data are self-explanatory of
the debated genetic eﬀect on the outcome of CI.
Although our initial aim was to evaluate the eﬀect
of GJB2 and GJB6 mutations on the outcome of CI in
children with congenital hearing loss, our patient population
appeared to have no GJB6 mutation. Previous studies had
reported GJB6 mutations to be rare or absent in the Iranian
population [21, 22]. Further studies on diﬀerent patient
populations might be done to assess whether our ﬁndings
can be generalized to patients with GJB6 mutations.
Our study is not without limitations. Similar to other
studies discussed above, we are unable to clarify the patho-
physiology of congenital hearing loss in the fraction with no
GJB2mutation.Answeringthisquestionneedsgenome-wide
studies which are beyond our scope. Additionally, because
the collection of audiological data was based on manual
reviewofmedicalrecords,wewereunabletocollectcomplete
dataonallpatients.Finally,asmentionedpreviously,weused
SAT, SRT, and MCL tests as our outcome measures due to a
lack of speech-level tests standardized for Persian language.
We suggest future researchers to validate open-set and close-
set tests for Persian language and use them as their outcome
measure.
In short, the ﬁndings of our study with a notable statis-
tical power are not in accordance with the assumption that
genetic mutations may be associated withdiﬀerent prognosis
afterCI.GiventheintensiveworkandtheexpensesofCIwith
limited resources, particularly for countries where implants
are used mainly for profoundly deaf children before the age
of 3, we cannot support the hypothesis that genetic testing
has a value to the CI procedure and its outcomes. When
limited resources and lack of insurance coverage for the
genetic tests are factored in, the costs of genetic testing can
signiﬁcantly overweigh its potential beneﬁt. In the absence
of larger studies with higher statistical power, a systematic
review may enlighten the eﬀect of mutations on the outcome
of cochlear implantation and also investigate the reason for
heterogeneous results of previous studies.
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